

PCT/IL 2004/000256

01 APR 2004

REC'D 21 APR 2004

WIPO

F

PA 1146201

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

March 22, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 60/455,567

FILING DATE: March 19, 2003

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

PRIORITY

By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS



P. Swain

P. SWAIN

Certifying Officer

60455567 031903

Please type a plus sign (+) inside this box



Docket Number:

1011/11

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53 (c).

INVENTOR(S)/APPLICANT(S)						
Given Name (first and middle (if any))		Family Name or Surname		Residence (City and either State or Foreign Country)		
GAL JOSEPH		YADID ZOHAR		SHOHAM, ISRAEL HERZLIAH, ISRAEL		
<input type="checkbox"/> Additional inventors are being named on page 2 attached hereto						
TITLE OF THE INVENTION (280 characters max)						
SCREENING FOR INNOVATIVE TREATMENT FOR POST- TRAUMATIC STRESS DISORDER USING MULTIDIMENSIONAL ANIMAL MODELS						
CORRESPONDENCE ADDRESS						
<input type="checkbox"/> Direct all correspondence to: Customer Number <input type="text"/> <div style="border: 1px solid black; padding: 5px; display: inline-block;">Place Customer Number Bar Code Label here</div>						
OR						
<input type="checkbox"/> Firm or Individual Name		Mark M. Friedman				
Address		c/o DISCOVERY DISPATCH				
Address		9003 FLORIN WAY				
City		State	MD	ZIP	20772	
Country		US	Telephone	301-9521011	Fax	301-9529023
ENCLOSED APPLICATION PARTS (check all that apply)						
<input checked="" type="checkbox"/>	Specification	Number of Pages	7	Applicant is Small Entity		
<input type="checkbox"/>	Drawing(s)	Number of Sheets		<input checked="" type="checkbox"/>	Other (specify) Assignment	
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT (check one)						
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees						
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number:						
				06-2140	FILING FEE AMOUNT \$80 +10	
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.						
<input checked="" type="checkbox"/> No.						
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are:						

Respectfully submitted,

SIGNATURE

DATE 17 Mar 03

TYPED or PRINTED NAME Mark M. Friedman

REGISTRATION NO. 33,883
(if appropriate)

TELEPHONE (703) 415-1581

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, DC 20231

p.1

SCREENING FOR INNOVATIVE TREATMENT FOR POST- TRAUMATIC STRESS DISORDER USING MULTIDIMENSIONAL ANIMAL MODELS

Inventors:

**Gal Yadid
HaMacabeem 88
Shoham
Israel**

**Joseph Zohar
24 Shlonsky Street
Herzliah 46767
Israel**

FIELD OF INVENTION

Post-traumatic stress disorder (PTSD) is a common condition, which affects about 6% of the general population and has severe impact on the quality of life. (Kessler et al., 1995). PTSD is currently defined by the coexistence of three clusters of symptoms: re-experiencing, avoidance and hyper-arousal, which persist for at least one month, in survivors of a traumatic event (American Psychiatric Association, 1994).

To date, there is still an ongoing search for treatment of PTSD. Although sertraline, the selective serotonin re-uptake inhibitor approved for PTSD, was found to be clinically effective, the result is still far from providing a full remission (Brady et al., 1995). Abnormal activity of the autonomic nervous system (ANS) (Stein et al., 2000) and of the hypothalamic-pituitary-adrenal (HPA) axis (Yehuda et al. 1991) has been suggested as the basis of some of the characteristic features of PTSD. However, the findings concerning adrenocortical dysfunction in PTSD patients remain unclear. Pitman and Orr (1990) reported high 24-hour urinary cortisol in veterans with PTSD compared to normal controls with combat experience. Conversely, four studies reported lower 24-hour urinary cortisol in PTSD patients compared to normal controls, and to depressed patients (Yehuda et al. 1990). Young et al. (1995) reported enhanced pituitary proopiomelanocortin (POMC) messenger ribonucleic acid (mRNA) expression and corticotropin (ACTH) storage. Kosten et al. (1997) also reported elevated epinephrine level during PTSD patients as compared to major depressive disorder, paranoid schizophrenia and undifferentiated schizophrenia.

DESCRIPTION OF INVENTION

Current studies of the available animal models for PTSD ignore the well-accepted clinical findings that only a minority (about 20%) of the individuals that are exposed to a traumatic event will eventually develop PTSD (Yehuda et al., 1995). The novelty of this invention is the ability to separate and identify those

animals, which, after exposure to trauma, will develop symptoms mimicking post-traumatic stress response. Therefore, the objectives of the present method are:

1. To recognize and analyze specifically the behavior of the animals which respond in an overly exaggerated way after exposure to events that remind the traumatic event. This most effectively mimics post-traumatic stress response as expressed in humans.
2. To characterize the PTSD model by three separate clusters of symptoms as found in clinical PTSD:
 - Re-experiencing
 - Avoidance
 - Hyper-arousal
3. To test different drugs on these three different clusters of PTSD symptoms, and to analyze the response accordingly.
4. To test preventative methods (including pharmacological interventions) of PTSD with intervention prior, during, or after the exposure.
5. To elucidate biochemical alterations before and after drug treatment in relation to each of the three characterized clusters of PTSD symptoms.
6. To test combined drug treatments on the basis of data derived from 2,3 and 4.

DESCRIPTION OF METHOD

Animals:

Adult male Sprague-Dawley rats weighing 150-200 gr. are used. Animals are habituated to the housing conditions and testing area for at least ten days. During that time, rats are handled once daily; the handling consists of picking the rats up with a gloved hand. The animals are housed four per cage (two rats that are exposed to stress and two additional rats for social behavior sampling) in an animal room with stable temperature, reversed 12 hours light/dark cycle, with *ad libitum* food and water. All testing is performed during the dark phase using a dim light.

Initial exposure:

Rats are exposed to a blanket with the smell of a cat for 30 minutes in a restricted environment i.e. cage or bordered area; this time point is called "zero time".

Re-exposure:

The rats are again exposed to a blanket, with a similar texture but without the smell, one week after initial exposure and again after one month. The controls in our model are rats that will be re-exposed to the blanket but will not go on to develop PTSD as opposed to animals that will display PTSD symptoms.

It is important to note that this model can be extended to any animal species exposed to any natural occurring stress (exposure to a predator underwater stress etc.)

BEHAVIORAL MEASUREMENT

Before exposure to the stressor, the animal is tested (videotaped) in an open field chamber alone (5 min) with its habituated companion rat (5 min) and during hyperarousal event (5 min). Immediately following re-exposure (both at "zero time", after one week and after one month) the rats are re-tested in an open field chamber in same conditions and paradigm. The animals are then screened according to the following parameters:

1) Self behaviour:

Observed Behaviour	Normal Threshold (% of total time)	PTSD (% of total time)
Freezing	0.5- 5	20- 80
Grooming	7-13	4-13
Sniffing	6-14	11-22
Climbing over	12-17	2-4
Staying in corner	29-43	51-75

2) Social interaction and avoidance:

The re-exposed animal is paired with a rat which has not been exposed to trauma and the following social interactions are observed.

Observed Behaviour	Normal Threshold (% of total time)	PTSD (% of total time)
Freezing	25-50	60-75
Grooming	11-17	0-2
Sniffing	8-16	26-42
Climbing over	6-12	7-13
Crawling under	0-2	2-4
Genital Investigation	0-2	0-2
Staying in corner	23-37	25-45

p.4

3) Hyper-arousal:

The re-exposed animal is subjected to loud clap, bang or any loud noise.

Observed Behaviour	Normal Threshold (% of total time)	PTSD (% of total time)
Freezing	5-70	90-100

BIOCHEMICAL TESTS

ACTH and corticosterone are measured in plasma samples with RIA kits. Biochemical testing is performed one week after the last exposure. PTSD rats according to behavioral measures showed either increased (X7) or decreased (X0.2). The HPA axis is indeed afflicted by stress. In the literature there are findings which report high 24-hour urinary cortisol in veterans with PTSD (Morgan et al, 2000) along with studies that report lower 24-hour urinary cortisol in PTSD patients (Yehuda et al, 1992).

POTENTIAL OF MODEL FOR DRUG SCREENING

The method enables screening for potential drugs in the treatment of PTSD including SSRIs, nerve-protecting agents, medications which alter the HPA axis, beta-blockers, etc. These medications are given either immediately after original exposure or after first re-exposure with the intention of testing as to whether these compounds prevent or decrease intensity or frequency of PTSD symptoms. Testing is carried out as previously described. Criteria for improvement is a decrease by more than 25% in each of the systems tested.

CONCLUSION:

Using the criteria outlined in this model, only 12% of the rats that are exposed to stress and then re-exposed develop symptoms characteristic of PTSD. Measurement of ACTH and corticosterone in plasma samples of the rats a week after the last behavioral measurement (month point time) show inconsistencies. Both these findings are consistent with human PTSD, emphasizing the reliability and validity of the model and providing new parameters which may correlate with the disease.

REFERENCES

American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th edn (DSM-IV) (American Psychiatric Press: Washington, DC, 1994).

Brady KT, Sonne SC, Roberts JM, Sertraline treatment of comorbid posttraumatic stress disorder and alcohol dependence. *J Clin Psychiatry* (1995) 56:502-5.

File SE, the interplay of learning and anxiety in the elevated plus-maze, *Behav Brain Res* (1993) 20:58(1-2):199-202.

Kessler RC, Sonnega A, Bromet EJ et al, Posttraumatic stress disorder in the National Comorbidity Survey, *Arch Gen Psychiatry* (1995) 52:1048-60.

Kosten TR, Ziedonis DM, Substance abuse and schizophrenia: editors' introduction, *Schiz Bull* (1997):23(2):181-6.

Morgan CA, 3rd, Wang S, Mason J, et al (2000): Hormone profiles in humans experiencing military survival training. *Biol Psychiatry* 47:891-901.

Morris RGM., development of a water-maze procedure for studying spatial learning in the rat, *Journal of neuroscience methods* 11,47-60.

Pitman RK, Orr SP, Twenty-four hour urinary cortisol and catecholamin excretion in combat-related posttraumatic stress disorder, *Biol Psychiatry* (1990) 15:27(2):245-7.

Stein DJ, Seedat S, Van der Linder, Kaminer D, Pharmacotherapy of post-traumatic stress disorder In "Post-traumatic Stress Disorder" Ed Natt D, Davidson J, Zohar J, Martin Dunitz Ltd.2000 London.2000 pp131-46.

Yehuda R, Giller EL, Southwick SM, Lowy MT, Mason JW, Hypothalamic pituitary-adrenal dysfunction in posttraumatic-stress-disorder, *Biol Psychiatry* (1991) 30:(10) 1031-48.

Yehuda R, McFarlane AC, Conflict between current knowledge about posttraumatic stress disorder and its original conceptual basis, *Am J Psychiatry* (1995) 152:1705-13.

p.6

Yehuda R, Southwick S, Giller EL, Ma X, Mason JW (1992): Urinary catecholamine excretion and severity of PTSD symptoms in Vietnam combat veterans. *J Nerv Ment Dis* 180:321-5.

Yehuda R, Southwick SM, Nussbaum G, Wahby V, Giller EL Jr, Mason JW, Low urinary cortisol excretion in patients with posttraumatic stress disorder. *J Nerv Ment Dis* (1990) 178(6):366-9.

Young EA, Kwak SP, Kottak J, Negative feedback regulation following administration of chronic exogenous corticosterone, *J Neuroendocrinol* (1995) 7(1):37-45.

WHAT IS CLAIMED IS:

1. A method for producing an animal with symptoms mimicking post-traumatic stress disorder, the method comprising:
 - a. exposing the animal to a trauma-inducing stimulus
 - b. re-exposing the animal to the stimulus
 - c. determining if the animal exhibits at least one behavioral response characteristic of post traumatic stress disorder, and
 - d. diagnosing the animal as having post traumatic stress disorder if the animal exhibits at least one behavioral response characteristic of post traumatic stress disorder.